Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 biomarker-driven alvocidib + chemotherapy in relapsed/refractory AML
2017-001178-41Phase 2Terminated
- Sponsor
- Tolero Pharmaceuticals
- Start
- Jul 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of alvocidib in acute myeloid leukemia (AML) (2 arms), sponsored by Tolero Pharmaceuticals. Primary endpoint: Complete remission rate after Cycle 1. Started Jul 2017; status: terminated.
02
Drugs
alvocidib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2017-001178-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001178-41.